Literature DB >> 17275070

Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification.

Géraldine Pignot1, Caroline Elie, Sophie Conquy, Annick Vieillefond, Thierry Flam, Marc Zerbib, Bernard Debré, Delphine Amsellem-Ouazana.   

Abstract

OBJECTIVES: To evaluate the prognostic significance of subtyping papillary renal cell carcinoma (PRCC) into type 1 and type 2 tumors.
METHODS: From 1995 to 2004, 1358 patients underwent surgery for renal cell carcinoma, of whom 130 had PRCC alone on the specimen. The tumor characteristics, including their subtype, were analyzed; small basophilic cells and large eosinophilic cells were defined type 1 and type 2 tumors, respectively. Survival analyses were performed retrospectively.
RESULTS: Of the 130 patients (110 men and 20 women, mean age 60.6 +/- 15.3 years) with PRCC, 102 underwent radical nephrectomy (78.4%) and 28 underwent partial nephrectomy (21.6%). The median tumor size was 4.5 cm (range 0.5 to 21). The comparison of the 68 (52.3%) type 1 PRCCs and 62 (47.7%) type 2 PRCCs revealed that type 2 tumors were associated with a greater stage and grade and microvascular invasion significantly (P <0.001) more often. The median follow-up was 48 months (range 2 to 111). Of the 130 patients, 22 died of cancer-specific causes, 5 (7%) with type 1 and 17 (27%) with type 2 tumors (P = 0.002). The overall and disease-free survival rate was 89% and 92% in type 1 tumors and 55% and 44% in type 2 tumors, respectively. Univariate analysis identified tumor type, stage (P <0.001), grade (P <0.001), microvascular invasion (P <0.001), an absence of foam cells (P <0.001), the presence of sarcomatoid cells (P = 0.001), and tumor necrosis (P = 0.007) as prognostic factors. Multivariate analysis retained tumor type (P = 0.034) and TNM stage (P <0.001).
CONCLUSIONS: The results of our study have shown that histologic subtyping of PRCC allows for the identification of an independent prognostic factor.

Entities:  

Mesh:

Year:  2007        PMID: 17275070     DOI: 10.1016/j.urology.2006.09.052

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  63 in total

1.  Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis.

Authors:  T Urge; O Hes; J Ferda; Z Chudácek; V Eret; M Michal; M Brunelli; G Martignoni; M Hora
Journal:  World J Urol       Date:  2010-05-08       Impact factor: 4.226

Review 2.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.

Authors:  Wong-Ho Chow; Brian Shuch; W Marston Linehan; Susan S Devesa
Journal:  Cancer       Date:  2012-11-12       Impact factor: 6.860

Review 4.  Solid renal masses: what the numbers tell us.

Authors:  Stella K Kang; William C Huang; Pari V Pandharipande; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

Review 5.  Targeted therapeutic strategies for the management of renal cell carcinoma.

Authors:  Eric A Singer; Gopal N Gupta; Ramaprasad Srinivasan
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

6.  Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.

Authors:  H Borgmann; M Musquera; A Haferkamp; A Vilaseca; T Klatte; S F Shariat; A Scavuzzo; M A Jimenez Rios; I Wolff; U Capitanio; P Dell'Oglio; L M Krabbe; E Herrmann; T Ecke; D Vergho; N Huck; N Wagener; S Pahernik; S Zastrow; M Wirth; C Surcel; C Mirvald; K Prochazkova; G Hutterer; R Zigeuner; L Cindolo; M Hora; C G Stief; M May; S D Brookman-May
Journal:  World J Urol       Date:  2017-08-23       Impact factor: 4.226

7.  Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches.

Authors:  Ivan Zokalj; Miljenko Marotti; Branko Kolarić
Journal:  Int Urol Nephrol       Date:  2014-01-01       Impact factor: 2.370

Review 8.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Urol Clin North Am       Date:  2018-06-15       Impact factor: 2.241

9.  Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma.

Authors:  Carl Ludwig Behnes; Felix Bremmer; Bernhard Hemmerlein; Arne Strauss; Philipp Ströbel; Heinz-Joachim Radzun
Journal:  Virchows Arch       Date:  2013-12-11       Impact factor: 4.064

10.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.